|
Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC). |
| |
|
Honoraria - EMD Serono; Pfizer/EMD Serono |
Research Funding - Amgen (Inst); Apollomics (Inst); Arcus Biosciences (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HUYA Bioscience International (Inst); Nektar (Inst); Prometheus; Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Seagen (Inst) |
| |
|
Honoraria - Astellas Scientific and Medical Affairs Inc; Bristol-Myers Squibb; EMD Serono; Pfizer/EMD Serono |
Consulting or Advisory Role - Algeta/Bayer; Amgen; AstraZeneca; AstraZeneca/MedImmune; AVEO; Bayer; Dendreon; EMD Serono; Exelixis; Immunomedics; Janssen Biotech; Merck; Pfizer; Pfizer/Myovant; Sanofi; Seagen |
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho; Seattle Genetics/Astellas; Seattle Genetics/Astellas |
Travel, Accommodations, Expenses - Algeta/Bayer; Astellas Pharma; Bristol Myers Squibb; Dendreon; EMD Serono |
| |
|
|
| |
|
Employment - Genesis Research |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Merck KGaA |
| |
|
Employment - Genesis Research |
| |
|
Employment - Genesis Research |
| |
|
Employment - Genesis Research |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
| |
|
|
| |
|
|
| |
|
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma |
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst) |